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Francisella (F.) philomiragia is a Gram-negative bacterium with a preference for brackish
environments that has been implicated in causing bacterial infections in near-drowning
victims. The purpose of this study was to characterize the ability of F. philomiragia
to infect cultured mammalian cells, a commonly used invertebrate model, and, finally,
to characterize the ability of F. philomiragia to infect BALB/c mice via the pulmonary
(intranasal) route of infection. This study shows that F. philomiragia infects J774A.1
murine macrophage cells, HepG2 cells and A549 human Type II alveolar epithelial cells.
However, replication rates vary depending on strain at 24 h. F. philomiragia infection
after 24 h was found to be cytotoxic in human U937 macrophage-like cells and
J774A.1 cells. This is in contrast to the findings that F. philomiragia was non-cytotoxic
to human hepatocellular carcinoma cells, HepG2 cells and A549 cells. Differential
cytotoxicity is a point for further study. Here, it was demonstrated that F. philomiragia
grown in host-adapted conditions (BHI, pH 6.8) is sensitive to levofloxacin but shows
increased resistance to the human cathelicidin LL-37 and murine cathelicidin mCRAMP
when compared to related the Francisella species, F. tularensis subsp. novicida and
F. tularensis subsp. LVS. Previous findings that LL-37 is strongly upregulated in
A549 cells following F. tularensis subsp. novicida infection suggest that the level of
antimicrobial peptide expression is not sufficient in cells to eradicate the intracellular
bacteria. Finally, this study demonstrates that F. philomiragia is lethal in two in vivo
models; Galleria mellonella via hemocoel injection, with a LD50 of 1.8× 103, and BALB/c
mice by intranasal infection, with a LD50 of 3.45 × 103. In conclusion, F. philomiragia
may be a useful model organism to study the genus Francisella, particularly for those
researchers with interest in studying microbial ecology or environmental strains of
Francisella. Additionally, the Biosafety level 2 status of F. philomiragia makes it an
attractive model for virulence and pathogenesis studies.
Keywords: Francisella philomiragia, murine model, mammalian cells, Galleria mellonella, pulmonary infection,
intranasal
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INTRODUCTION
Members of the Francisella genus are small, non-motile, Gram-
negative coccobacilli of the gamma-proteobacteria class (Sjostedt,
2007). Francisella philomiragia was first identified in an ailing
muskrat located in Utah approximately 50 years ago, following
the discovery of its related species, F. tularensis (Hollis et al.,
1989). Mistakenly characterized as Yersinia philomiragia due to
its 24% genomic homology with Y. pestis and similarities in
morphology, it took 30 years to re-categorize the species as a
member of the Francisella genus (Hollis et al., 1989).
Francisella philomiragia has an affinity for aquatic
environments which may increase its host species potential
(Anda et al., 2001; Tarnvik et al., 2004). The natural range of
F. philomiragia reflects its preference for aquatic environments
as it is found near bodies of water, particularly brackish or salt
water in the mainland United States (Hollis et al., 1989; Whipp
et al., 2003; Berrada and Telford, 2010; Siddaramappa et al., 2012;
Whitehouse et al., 2012). F. philomiragia may exist naturally
by forming biofilms on exposed surfaces of the environment
and infecting the aquatic amoeba, Acanthamoeba castellanii
(Verhoeven et al., 2010).
Virulence factors in F. philomiragia have not been well
studied in this species, but likely include proteins encoded by
the Francisella Pathogenicity Island (FPI) and phospholipase C
(Zeytun et al., 2012), similar to other members of the Francisella
genus (Nano and Schmerk, 2007; Dai et al., 2010).
A related species, F. noatunensis (formerly named
F. philomiragia noatunensis), is pathogenic to many fish
and mollusk species, which inflicts negative economic and health
effects on fisheries (Kay et al., 2006; Ostland et al., 2006; Mauel
et al., 2007; Mikalsen and Colquhoun, 2009). Mikalsen et al.
(2009) previously asserted that F. philomiragia subsp. noatunensis
is a fish pathogen that is not lethal to mice and does not pose a
threat to human health (Mikalsen et al., 2009). However, in the
time since that publication, F. noatunensis has been elevated to
species level, which leaves the ability of F. philomiragia to infect
mice in question and untested (Mikalsen and Colquhoun, 2009;
Cowley and Elkins, 2011).
Near-drowning victims are susceptible to numerous bacterial
infections due to the direct inoculation of the bacteria into the
lungs (Ender and Dolan, 1997; Relich et al., 2015). F. philomiragia
infections have been reported in otherwise healthy individuals via
direct lung exposure resulting from near-drowning experiences
in brackish or salty water or immunocompromised individuals
with contact to contaminated water or fish (Wenger et al.,
1989; Ender and Dolan, 1997; Cora et al., 2010; Kreitmann
et al., 2015). Despite differences in genomic sequences (88%
homologous to F. tularensis subsp. LVS and 84% to F. tularensis
subsp. novicida and SchuS4; Zeytun et al., 2012; Davenport et al.,
2014; Johnson et al., 2015), slightly different plasmids (Le Pihive
et al., 2009), and reports that F. philomiragia does not cause
disease in mice (Mikalsen et al., 2009), some of these near
drowning victims infected by F. philomiragia develop a severe
pneumonic infection. This prompted further investigation on
the similarity of F. philomiragia to F. tularensis subsp. novicida
and subsp. LVS, strains related to virulent F. tularensis subsp.
SchuS4, and whether it may be an opportunistic pathogens in
humans. This comparison was achieved through the use of
in vitro experiments using cell models involved in tularemia
infections (macrophages, lungs, and liver) and in vivo animal
infection models (G. mellonella and BALB/c mice).
MATERIALS AND METHODS
Bacterial Strains
Francisella tularensis Live Vaccine Strain (LVS; ATCC 29684),
F. tularensis subsp. novicida (ATCC 15482), and F. philomiragia
(ATCC 25015) were obtained from the American Type Culture
Collection (Manassas, VA, USA). All bacterial strains were
streaked onto Chocolate II Agar (GC II Agar with Hemoglobin
and IsoVitaleXTM, BD 221267) and single colonies were
inoculated into Brain Heart Infusion (BHI pH 6.8) broth
(TekNova, Hollister, CA, USA).
Tissue Culture Cells
Murine macrophages, J774A.1 (ATCC TIB-67), human
hepatocellular carcinoma cells, HepG2 (ATCC HB-8065),
and human Type II alveolar epithelial cells, A549 (ATCC
CCL-185), were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM; Invitrogen #10566-016) supplemented with 10% fetal
bovine serum (FBS) as per the manufacturer’s recommendations.
Human U937 macrophage-like cells (ATCC CRL-1593.2), were
cultured in RPMI 1640 media with 2 mM L-glutamine and
10% FBS as per the manufacturer’s recommendations (Lonza
# 3163826). U937 cells were differentiated from monocytes to
macrophages as instructed by manufacturer.
Infection Protocol for A549, J774A.1,
HepG2, and U937 Cells
Cells were infected at a multiplicity of infection (MOI) of
approximately 500, as previously described (Han et al., 2008;
Hegedus et al., 2008; Ahmad et al., 2010), with a 2-h preinfection
and 1-h gentamicin pulse. Briefly, cells were seeded (105/well) in
a 48-well plate and allowed to attach overnight. After verifying
successful cell attachment, culture media was gently removed and
rinsed twice with culture media. Francisella strains were grown
to mid-logarithmic phase, collected by centrifugation (10 min at
4000 × g, 4◦C), washed three times with 1x phosphate buffered
saline (PBS), and diluted in serum-free DMEM to a verified
bacterial concentration (CFU/mL). Dilutions of bacteria were
used to infect each cell line at MOI = 500. Sets of three wells
were prepared for each condition (n = 3). Characteristically,
Francisella infects host cells inefficiently, despite its infectivity via
multiple routes in animals and humans. Therefore, the standard
MOI of 500 CFU was used to infect cells with the Francisella
strains in order to achieve infection of most of the cells (Lai
et al., 2001; Lai and Sjostedt, 2003). Cells were then incubated
with bacteria at 37◦C, 5% CO2. After a 2-h incubation, well
media was gently aspirated, washed twice with PBS, and treated
with 50 µg/mL gentamicin in serum-free DMEM for 1 h to kill
extracellular bacteria. Following the gentamicin pulse, cell media
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was gently aspirated, replaced with DMEM supplemented with
10% FBS and 5 µg/mL gentamicin, and allowed to incubate for
24 h at 37◦C, 5% CO2. (Lai et al., 2001; Han et al., 2008; Ahmad
et al., 2010) Cells were lysed and plated on Chocolate agar for
CFU determination.
Cytotoxicity Assay of Mammalian Tissue
Cultured Cells Infected with Francisella
PrestoBlue Cell Viability Reagent (A-13261, Life Technologies,
Carlsbad, CA, USA) was used according to the manufacturer’s
protocol. This reagent functions by using the reducing
environment of the cell’s cytosol to determine cell viability.
The reagent contains a cell-permeable compound, which is
blue in color. When added to viable cells, it encounters the
reducing environment and modifies the reagent to become a red
fluorescent, which can be detected by fluorescence or absorbance
measurements. Briefly, reagent was added to infected cells 24 h
post gentamicin-pulse at a 1:10 ratio. The reagent was incubated
with cells at 37◦C for 2 h. Fluorescence was measured at
excitation and emission spectra of 560 and 590 nm, respectively.
Three wells were used per condition (n = 3). Data was averaged
and a no-cell well was subtracted as background. Data was then
plotted using GraphPad Prism 5 (GraphPad Software Inc., San
Diego, CA, USA) to reflect the cytotoxic effect of Francisella
species on eukaryotic cell lines.
EC50 Antimicrobial Assays
Peptides used in this study were custom synthesized by
ChinaPeptides Company (Shanghai, China) and had purities
of ≥95% based on chromatographic analysis of the purified
peptides. Antimicrobial activity (EC50) assays of the antibiotic
control levofloxacin, human cathelicidin LL-37, and murine
cathelicidin mCRAMP were performed against F. philomiragia,
F. tularensis subsp. novicida, and F. tularensis subsp. LVS as
previously described (Amer et al., 2010). Briefly, 1 × 105
CFU/well of Francisella species were grown in BHI (pH 6.8),
added to a sterile 96-well plate and incubated with serial dilutions
of peptide or antibiotic in 10 mM phosphate buffer for 3 h at
37◦C. Dilutions were plated in triplicate on tryptic soy agar with
1% cysteine for 24 h; colonies were counted to determine survival
(n = 3). This experiment was performed three independent
times. Bacterial survival was calculated by a ratio of the number
of colonies on each experimental plate to the average number
of colonies on the control plates lacking peptide or antibiotic
application. The EC50 was determined using GraphPad Prism
5 (GraphPad Software Inc., San Diego, CA, USA) to plot the
percent survival versus log of peptide or antibiotic concentration
(log µg/mL) and fitting data to a standard sigmoidal dose–
response curve as previously described (Blower et al., 2015).
Waxworm Infection
Galleria mellonella larvae (Vander horst Wholesale, St. Mary’s,
OH, USA, 16 per group) were infected following previous reports
(Aperis et al., 2007; Dean et al., 2011; McKenney et al., 2012).
G. mellonella were infected by injecting 10 µL of bacteria into
the hemocoel via a right proleg and incubated at 37◦C. Each larva
received bacterial concentrations of 1 × 106, 5 × 105, 1 × 105,
5 × 104, 1 × 104, 5 × 103, 1 × 103, 5 × 102, or 1 × 102 CFU/mL
with 16 larvae per group. Waxworms were examined once a day
for death. Bacterial concentrations were verified via retrospective
plating and counting of CFUs.
Murine Infection
BALB/c mice (Harlan, Frederick, MD, USA, five per group) were
infected intranasally with 20 µL of the following concentrations
of bacteria: 1 × 106, 5 × 105, 1 × 105, 5 × 104, 1 × 104, 5 × 103,
or 1 × 103 CFU/20 µL. Mice were examined twice a day for
signs of illness or death. Bacterial concentrations were verified via
retrospective plating and counting of CFUs. Animal experiments
were approved by and conducted in compliance with regulations
of the Institutional Animal Care and Use Committee (Protocol #
0236) of George Mason University. All experiments were carried
out in accordance with the National Research Council’s Guide for
the Care and Use of Laboratory Animals (2011) and the Public
Health Service Policy on Humane Care and Use of Laboratory
Animals (2002).
Statistical Analysis
Antimicrobial EC50 assays were performed in triplicate with
n = 3 for each experiment, and representative experiments
are shown. Standard deviations of the mean of each set are
represented on each graph as error bars. Additionally the
confidence interval (95%) is provided for EC50 determinations
to demonstrate statistical overlap of data. Student’s t-test was
performed and p values of p < 0.05 was considered statistically
different.
The survival curves were performed with an n = 16 for
G. mellonella and an n = 5 for BALB/c mice and were analyzed
using the Mantel–Cox test, which is used to test the null
hypothesis that survival curves are not different between groups.
This test does not assume a normal distribution, allows for
censored data, and is based off of the chi-squared test, which
allows for a minimum of five samples.
RESULTS
During pulmonary tularemia infections, bacteria colonize the
alveolar macrophages, the lungs, and the liver (Hall et al., 2007;
Faron et al., 2015). F. philomiragia was evaluated to see if it
infected cell lines representative of these systems in vitro: murine
macrophage cells, J774A.1, human Type II alveolar epithelial
cells, A549, and human hepatocyte-like cells, HepG2. These
cell lines have been previously shown by us and others to be
susceptible to infection by F. tularensis subsp. novicida and LVS
(Qin and Mann, 2006; Han et al., 2008; Amer et al., 2010;
Bradburne et al., 2013).
Francisella tularensis readily infects macrophages and
proliferates within these cells (Anthony et al., 1991; Golovliov
et al., 1997; Lai et al., 2001; Bolger et al., 2005). It is characteristic
for Francisella replication to occur with little cytotoxicity until
the cell becomes overburdened (at about 48 h post infection) and
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will experience cell death. F. philomiragia was found to be able to
infect and proliferate in murine macrophages at 24 h to higher
levels than what was seen for F. tularensis subsp. novicida and
subsp. LVS (Figure 1A, p < 0.05). These results with the in vitro
FIGURE 1 | Bacterial replication following infection of cultured
mammalian cells. Francisella philomiragia, F. tularensis subsp. novicida, and
F. tularensis subsp. LVS infection of (A) murine macrophage J774A.1 cells, (B)
human lung epithelial A549 cells, and (C) human hepatocytes HepG2 cells.
macrophage model suggest that F. philomiragia may be capable
of infecting mammalian macrophages in vivo. Furthermore,
these results suggest that F. philomiragia may be able to infect
the alveolar macrophages in the lungs of near-drowning victims,
which results in the clinical disease resembling tularemia that
can aﬄict these patients.
Human alveolar epithelial cells are known to be infected by
Francisella both in vitro and in vivo (Hall et al., 2007; Faron
et al., 2015). Here, experiments utilizing A549 cells showed
that F. philomiragia infects this cell type to a lesser extent
than F. tularensis subsp. novicida but more than subsp. LVS
(Figure 1B, p < 0.05). The infection of this cell type suggests
another potential mechanism by which the near-drowning
infections in human could occur by this organism due to the
direct inoculation of the lung.
Francisella infection of and proliferation in hepatocytes has
been observed in human tularemia patients and animal models
(Conlan and North, 1992; Lamps et al., 2004; Rasmussen et al.,
2006; Ray et al., 2010). The fully virulent F. tularensis subsp.
SchuS4 replicates well in cultured HepG2 cells (Qin and Mann,
2006). In these experiments, F. tularensis subsp. LVS infected
human hepatocyte-like cells well, and replicated faster than
F. tularensis subsp. novicida and F. philomiragia. However, by
24 h post infection, there were no differences between the
bacterial burdens of the three Francisella species in HepG2 cells
(Figure 1C, p > 0.05). This suggests that the F. philomiragia
infections could potentially lead to liver damage, consistent with
a tularemia infection.
Francisella tularensis is said to be a “stealth” pathogen,
promoting its intracellular survival by not causing high
cytotoxicity, among other mechanisms (Sjostedt, 2006; Jones
et al., 2014). It was previously shown that infections of A549 cells
by F. tularensis subsp. LVS (at 500 MOI) for 24 h did not cause
significant cytotoxicity, although CFU increased significantly
(Han et al., 2008; Bradburne et al., 2013). This high MOI of 500 is
standard for Francisella infection protocols, as it is not taken up
into non-phagocytic cells readily (Lai et al., 2001; Lai and Sjostedt,
2003; Telepnev et al., 2003). These studies were expanded to
all three strains of Francisella investigated here (F. tularensis
subsp. LVS, F. tularensis subsp. novicida, and F. philomiragia) and
J774A.1, A549, and HepG2 cells.
This study confirmed that F. tularensis subsp. LVS is not
significantly cytotoxic toward A549 cells and, furthermore, it was
found that F. tularensis subsp. novicida and F. philomiragia also
displayed little cytotoxicity in this cell line at 24 h (Figure 2).
HepG2s were also minimally affected by cytotoxic effects of
F. tularensis subsp. LVS and displayed only 10 and 8% cytotoxicity
from F. tularensis subsp. novicida and F. philomiragia infections
at 24 h, respectively. The murine macrophage cell line, J774A.1,
demonstrated greater susceptibility to the cytotoxic effects of
Francisella, with all strains demonstrating about 33% cytotoxicity
at 24 h (p < 0.05) consistent with previous reports (Lai et al.,
2001; Lai and Sjostedt, 2003). However, additional cytotoxicity
studies showed that F. philomiragia is highly cytotoxic to the
human macrophage-like cell line, U937, (33%, p < 0.05) while
F. tularensis subsp. LVS and subsp. novicida showed only 7
and 5% cytotoxicity, respectively. The differences between the
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FIGURE 2 | Cytotoxicity of Francisella strains to cultured mammalian
cells. Cytotoxicity of F. philomiragia to cultured mammalian cells, compared
to F. tularensis subsp. LVS and F. tularensis subsp. novicida.
human and murine macrophage cell lines are not yet understood
in regard to Francisella infections. Previously, differences in
Francisella intracellular replication have been noted between rat
and murine macrophages (Anthony et al., 1991), however, other
causes for the cytotoxicity differences other than species of origin
are possible. These findings are consistent with the intracellular
replication lifestyle of other Francisella species (Sjostedt, 2006).
Here, F. philomiragia was found to infect and replicate in the
same cell types and have the same general level of cytotoxicity in
those cell types as F. tularensis subsp. LVS and subsp. novicida,
with the exception of the U937 cells (p< 0.05). The susceptibility
of F. philomiragia to two antimicrobial peptides, LL-37, a human
cathelicidin, and mCRAMP, a murine cathelicidin, known to
be expressed by host cells and have killing activity against
F. tularensis subsp. novicida and subsp. LVS was examined (Amer
et al., 2010). This is important because host defense against
Francisella infection relies not only on antibody production, but
also on the response of the innate immune system (Allen, 1962;
Metzger et al., 2007; Kirimanjeswara et al., 2008).
Francisella species, including F. philomiragia, are known to be
highly susceptible to levofloxacin under MIC conditions (Nelson
et al., 2010; Georgi et al., 2012), thus it was used as a control
for the EC50 antimicrobial assays. The EC50 for levofloxacin of
F. philomiragia is 0.0146 µg/mL (14.6 ng/mL; Figure 3A) while
the F. tularensis subsp. LVS EC50 is 0.00827 µg/mL (8.27 ng/mL)
and the F. tularensis subsp. novicida EC50 is 0.00843 µg/mL
(8.43 ng/mL; Table 1). These values are statistically the same
within the 95% confidence intervals (p> 0.05) and are consistent
with the MICs previously reported (Georgi et al., 2012).
The sensitivity of F. philomiragia to cationic antimicrobial
peptides has not been well studied. This organism is highly
resistant to colistin and polymyxin B, which are cationic
cyclic peptide antibiotics (Petersen et al., 2009; Stephens et al.,
2016). It was previously demonstrated that expression of the
human cathelicidin LL-37 in A549 cells is strongly induced by
F. tularensis subsp. novicida infection (Amer et al., 2010). This is
of interest as Francisella bacteria replicate directly in the cytosol
of the infected cells (Wehrly et al., 2009), and thus the bacteria
may be able to be killed by expression of these innate immunity
peptides by the aﬄicted cell.
The antimicrobial peptides, LL-37 and mCRAMP, were
tested for their killing activity against F. philomiragia in
FIGURE 3 | Antimicrobial (EC50) assays for Francisella strains.
F. philomiragia, F. tularensis subsp. novicida, and F. tularensis subsp. LVS
susceptibility against (A) levofloxacin and the cathelicidins (B) LL-37 and (C)
mCRAMP.
10 mM phosphate buffer, pH 7.2. The EC50 of LL-37 against
F. philomiragia was determined to be 3.61 µg/mL (Figure 3B). In
contrast to Francisella sensitivity to LL-37 in other species (EC50
of 1.15 and 0.0724µg/mL in F. tularensis subsp. LVS and novicida;
Amer et al., 2010; Flick-Smith et al., 2013), F. philomiragia is
more resistant to this human cathelicidin peptide (p < 0.05).
The EC50 of LL-37 against F. tularensis subsp. novicida found
here is statistically similar to previously reported values due to
Frontiers in Microbiology | www.frontiersin.org 5 May 2016 | Volume 7 | Article 696
fmicb-07-00696 May 23, 2016 Time: 16:41 # 6
Propst et al. F. philomiragia Infection Models
TABLE 1 | Summary of Antimicrobial (EC50) assays for Francisella strains.
Francisella tularensis
subsp. LVS
Francisella tularensis
subsp. novicida
Francisella
philomiragia
Levofloxacin EC50 (µg/ml) 0.00827 0.00843 0.0146
95% CI (0.00524–0.0131) (0.00413–0.0172) (0.00696–0.0305)
mCRAMP EC50 (µg/ml) 0.381 0.0453 5.27
95% CI (0.239–0.607) (0.0284–0.0723) (2.93–9.46)
LL-37 EC50 (µg/ml) 1.15 0.0724 3.61
95% CI (0.604–2.18) (0.0331–0.158) (2.36–5.53)
EC50 values plus 95% confidence intervals for F. philomiragia, F. tularensis subsp. novicida, and F. tularensis subsp. LVS susceptibility against levofloxacin and the
cathelicidins LL-37 and mCRAMP.
overlapping 95% confidence interval values (Amer et al., 2010).
Some small difference could also be due to the “host-adapted
phenotype” growth conditions used to grow the bacteria for this
study (BHI pH 6.8) compared to growth in Tryptic Soy Broth
with Cysteine (TSB-C) media that was used previously (Amer
et al., 2010). Growth in BHI (pH 6.8) is known to alter the surface
carbohydrate and gene expression in a way that mimics the
“host-adapted” phenotype of Francisella (Zarrella et al., 2011). In
conclusion, F. philomiragia is more resistant to LL-37 than other
Francisella species that were verified here (F. tularensis subsp.
LVS EC50 = 1.15 (threefold), p = 0.011, and F. tularensis subsp.
novicida EC50 = 0.0724µg/mL (50-fold), p= 0.0011; Amer et al.,
2010; Flick-Smith et al., 2013).
Francisella susceptibility to mCRAMP has not been previously
reported. The EC50 of mCRAMP against F. philomiragia was
determined to be 5.27 µg/mL (Figure 3C). No previous
reports of Francisella susceptibility to mCRAMP were found;
however, for this murine cathelicidin peptide, F. philomiragia is
significantly more resistant (p < 0.05) than F. tularensis subsp.
novicida (EC50 = 0.0453 µg/mL) or F. tularensis subsp. LVS
(EC50 = 0.381 µg/mL). Here it was found that F. philomiragia
is 14–116-fold more resistant to mCRAMP (EC50 = 5.27 µg/mL)
than F. tularensis subsp. LVS (0.381µg/mL, p= 0.007) and subsp.
novicida (0.0453 µg/mL, p= 0.0051).
This increased resistance of F. philomiragia to cationic
antimicrobial peptides could be due to differences in the LPS
(Siddaramappa et al., 2012) or other surface properties of
F. philomiragia compared to F. tularensis subsp. novicida or LVS
perhaps due to differential expression of high-molecular weight
carbohydrates in the “host-adapted” phenotype (Zarrella et al.,
2011).
Galleria mellonella has been demonstrated to be a useful
model for Francisella infection (Aperis et al., 2007; Ahmad et al.,
2010; McKenney et al., 2012; Sprynski et al., 2014), thus a
survival curve evaluating the mortality of G. mellonella during
F. philomiragia infection was examined. As shown in Figure 4A,
F. philomiragia injection is lethal to G. mellonella in a manner
similar to F. tularensis subsp. LVS (Aperis et al., 2007; Ahmad
et al., 2010). The LD50 of F. philomiragia in G. mellonella is
∼1.8× 103 CFU/mL or∼18 CFU with an inoculation volume of
10 µL. For comparison, the LD50 of F. tularensis subsp. novicida
in G. mellonella is ∼1.2 × 102 CFU/mL or ∼1 CFU due to an
inoculation volume of 10 µL (McKenney et al., 2012). The mean
and median times to death for F. philomiragia are 2.79 and 3 days,
respectively. Since F. philomiragia is able to infect G. mellonella
similarly to other laboratory strains of Francisella, infection of
BALB/c mice by the intranasal route of infection was tested for
this organism.
BALB/c mice are a common experimental model for
Francisella infections and they are susceptible to Francisella
infection by the pulmonary route (intranasal or aerosol), among
other routes; no studies have been reported for F. philomiragia
infections of insect models, mice, rats, or marmosets (Chen et al.,
2003; Conlan et al., 2003; Cowley and Elkins, 2011). To conform
to these standards and expand the in vivo results obtained
with G. mellonella, a survival curve evaluating the lethality of
F. philomiragia in BALB/c mice when delivered via intranasal
administration (mimicking near-drowning experiences) was
examined. As shown in Figure 4B, intranasal F. philomiragia is
lethal to BALB/c mice with an approximate LD50 of 3.45 × 103
FIGURE 4 | In vivo survival assays. F. philomiragia survival curve in
(A) G. mellonella and (B) BALB/c mice infected by the pulmonary route.
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CFU. This is very comparable to the intranasal F. tularensis subsp.
LVS LD50 (1× 103 CFU) in the same species of mice but is higher
than the 100 CFU intranasal LD50 of F. tularensis subsp. novicida
(Aperis et al., 2007).
DISCUSSION
Multiple reports of severe pneumonic infections of humans
following near-drowning experiences (Hollis et al., 1989; Wenger
et al., 1989) suggested that direct or large inoculation of
F. philomiragia into the lung by this method is sufficient to
allow for infection of normal, healthy human lungs, potentially
via infection of the alveolar macrophages and/or lung epithelial
cells. However, this organism is not generally regarded as a
human pathogen and its ability to infect mammalian cells
is generally uncharacterized. In addition, the highly related
organism, F. noatunensis, was found to be unable to infect
laboratory mice (Mikalsen et al., 2009). Thus, F. philomiragia
was compared to F. tularensis subsp. novicida and subsp. LVS
regarding its ability to infect human and murine cells was further
studied.
Francisella philomiragia was shown to be capable of infecting a
murine macrophage cell line, J774A.1, which are commonly used
for Francisella studies, with statistically higher levels (p < 0.05)
than more commonly studied strains of Francisella (Hegedus
et al., 2008; Pechous et al., 2008; Ahmad et al., 2010). Similarly,
F. philomiragia was also found to infect a human Type II
alveolar epithelial cell line, A549, at statistically higher levels
than F. tularensis subsp. LVS. This is the first demonstration of
F. philomiragia infecting Type II alveolar epithelial cells and is
a significant contribution to the understanding of the potential
interactions of F. philomiragia within the human lung. These
findings suggest a potential mechanism by which near-drowning
in brackish water known to contain F. philomiragia (Ottem et al.,
2007) could potentially lead to infection through interaction of
the bacteria with Type II alveolar epithelial cells of the lung
and/or alveolar macrophages (Gentry et al., 2007; Hall et al.,
2007; Craven et al., 2008; Faron et al., 2015). Furthermore, these
results suggest that aerosol exposure to F. philomiragia could
potentially lead to pulmonary infections in humans if inhaled
via an aerosol. Given the wide distribution of F. philomiragia, in
particular its known presence in various bodies of water within
the United States, this potential route of infection should be
further investigated.
In addition, it was demonstrated that F. philomiragia infects
HepG2 cells, a human hepatocyte-like cell line. This finding
suggests that F. philomiragia may be able to replicate in the liver
in infected near-drowning victims. The liver is one of the main
organs infected by F. tularensis strains and liver failure following
overwhelming organ infection is thought to be the primary
cause of death in mice suffering from tularemia (Conlan and
North, 1992). Patients suffering from F. philomiragia pneumonia
should be closely observed for sequelae similar to those found in
tularemia infections caused by F. tularensis species.
Cytotoxicity data after 24 h of infection show that
F. philomiragia is similar to F. tularensis subsp. novicida
and subsp. LVS in most of the studied cell lines. Little cytotoxicity
was seen in A549 cells (∼0%, similar to other species) and HepG2
cells (8%, more than subsp. LVS but similar to subsp. novicida),
and moderate cytotoxicity in J774A.1 cells (32%, similar to other
species). However, the U937 human macrophage-like cell line
only showed high cytotoxicity (33%) from F. philomiragia and
not the other Francisella strains studied. This observation will be
the subject of future investigation to understand the difference in
U937 susceptibility.
Susceptibility testing using the antimicrobial peptides LL-
37, a human cathelicidin, and mCRAMP, a murine cathelicidin,
showed that these peptides were highly active in vitro against
F. philomiragia. Despite being active in killing the bacteria
in vitro, this antimicrobial peptide host defense mechanism
is clearly insufficient to control F. philomiragia infections in
infected cells or in vivo.
Francisella philomiragia was found to be lethal for both in vivo
models tested: G. mellonella and BALB/c mice. G. mellonella has
been demonstrated to be a useful in vivo model for Francisella
infection (Aperis et al., 2007; Ahmad et al., 2010; McKenney et al.,
2012; Sprynski et al., 2014), thus the survival of G. mellonella
during F. philomiragia infection was examined. In G. mellonella,
F. philomiragia was shown to be fatal in concentrations similar
to F. tularensis subsp. LVS, with an LD50 of 18 CFU. This
similarity supports the ability of G. mellonella to be used as an
effective model for Francisella infection but also suggests that
F. philomiragia is capable of infecting a range of hosts similar to
other Francisella strains.
Francisella philomiragia is not generally regarded as
a pathogen of humans or animals but is considered an
environmental species of the genus (Anda et al., 2001; Tarnvik
et al., 2004; Verhoeven et al., 2010). In some cases, F. philomiragia
infections in near-drowning victims individuals are observed
(Wenger et al., 1989; Ender and Dolan, 1997). An intranasal
infection of mice by F. philomiragia was used to mimic lung
exposure seen in drowning victims and test the susceptibility
BALB/c mice to this organism. F. philomiragia was shown
to be fatal in BALB/c mice by intranasal-delivered inoculum
concentrations similar to F. tularensis subsp. LVS, with an
LD50 of 3.45 × 103 CFU; however, this is significantly higher
than the 10 CFU LD50 seen with F. tularensis subsp. novicida.
Thus, contrary to the result for F. noatunensis (Mikalsen et al.,
2009), F. philomiragia is able to infect laboratory mice. These
results call for further studies to determine the full host range of
F. philomiragia.
CONCLUSION
These studies show that F. philomiragia results in similar in vitro
and in vivo infections to the F. tularensis subspecies novicida
and LVS for the evaluated strains. It was demonstrated for
the first time that there is potential for significant and robust
F. philomiragia infection in macrophages, lung, and liver cells.
F. philomiragia infection of human alveolar epithelial cells and
macrophages suggests a mechanism for infection in the lungs
of near-drowning patients. The high level of F. philomiragia
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intracellular replication in all three cell types suggests that
F. philomiragia follows an infection course similar to tularemia
caused by F. tularensis subspecies. It was previously demonstrated
that infections of G. mellonella and pulmonary infections of
BALB/c mice were fatal with similar LD50s to F. tularensis subsp.
LVS. The results of these in vitro and in vivo experiments confirm
earlier suggestions that F. philomiragia may be an emerging
opportunistic human pathogen (Mailman and Schmidt, 2005;
Sjodin et al., 2012) and that cellular and animal models of
Francisella infection could also be used to study F. philomiragia.
It would be of interest to evaluate all the available F. philomiragia
strains for their ability to infect the various tissue culture and
murine models.
It was found that F. philomiragia is comparable to the
other Biosafety level 2 strains of Francisella in many respects
but unusual in its effect on human U937 cells. This finding
will open some interesting new avenues of research regarding
pathogenesis and virulence of F. philomiragia. In addition,
this work also positions F. philomiragia as another important
organism in the field of Francisella research, especially for
researchers interested in questions of microbial ecology
or environmental persistence of members of the genus
Francisella.
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